Literature DB >> 7522296

Recent progress in chronic lymphocytic leukemia. International Workshop on chronic Lymphocytic Leukemia.

R P Gale1, F Caligaris-Cappio, G Dighiero, M Keating, E Montserrat, K Rai.   

Abstract

The data we discuss indicate substantial recent progress in understanding and treating CLL. However, despite considerable new information, many of the intriguing issues we posed at previous IWCLL meetings remain unanswered. Prominent among these are the questions of what causes CLL, what is the relation between CLL and normal B-cell development, are T-cell abnormalities a cause of consequence of CLL, why are auto-immune features so prominent and how is CLL best treated? Although these gaps in our knowledge are unfortunate, they give us the opportunity for yet another IWCLL meeting: 1996 in Greece. More to follow.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7522296

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  5 in total

1.  Lack of intraclonal diversification in Ig heavy and light chain V region genes expressed by CD5+IgM+ chronic lymphocytic leukemia B cells: a multiple time point analysis.

Authors:  E W Schettino; A Cerutti; N Chiorazzi; P Casali
Journal:  J Immunol       Date:  1998-01-15       Impact factor: 5.422

Review 2.  Midkine as a regulator of B cell survival in health and disease.

Authors:  Sivan Cohen; Idit Shachar
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

3.  PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL.

Authors:  Dalia El-Gamal; Katie Williams; Taylor D LaFollette; Matthew Cannon; James S Blachly; Yiming Zhong; Jennifer A Woyach; Erich Williams; Farrukh T Awan; Jeffrey Jones; Leslie Andritsos; Kami Maddocks; Chia-Hsien Wu; Ching-Shih Chen; Amy Lehman; Xiaoli Zhang; Rosa Lapalombella; John C Byrd
Journal:  Blood       Date:  2014-07-07       Impact factor: 22.113

4.  Bone marrow dendritic cells support the survival of chronic lymphocytic leukemia cells in a CD84 dependent manner.

Authors:  Avital F Barak; Hadas Lewinsky; Michal Perpinial; Victoria Huber; Lihi Radomir; Mattias P Kramer; Lital Sever; Yochai Wolf; Mika Shapiro; Yair Herishanu; Steffen Jung; Shirly Becker-Herman; Idit Shachar
Journal:  Oncogene       Date:  2019-11-26       Impact factor: 9.867

Review 5.  Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites.

Authors:  Mona Darwish; Mary Bond; Edward Hellriegel; Philmore Robertson; James P Chovan
Journal:  Cancer Chemother Pharmacol       Date:  2015-04-01       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.